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All 28 serum samples were then tested blindly for the pres-
ence of HCV RNA sequences by a standard HCV RNA reverse
transcription-nested PCR protocol [2]. In accord with our pre-
vious experience with diagnosing human immunodeficiency
virus by PCR [3], we tested samples with two sets of primers
(two in- and two out-primers), both coding for sequences in the
5' noncoding region of the HCV genome [I, 2]. Samples were
considered reactive if they showed one positive result out of two
amplifications. Positive samples were those that showed two
positive results after amplification with the two primer sets
(table I).
Ifone considers that all samples showing at least one positive
PCR result are viremic, a good correlation can be established
between PCR and RIBA-2 results. Five samples were PCR- and
RIBA-positive. Four were PCR-reactive and RIBA-positive. Al-
though reactive samples were generally positive with one primer
set, the use ofa second set made it possible to detect reactivity in
I more patient. This fact enforces our theory that multiple
primer pairs should be routinely used for virus diagnostic pur-
poses. In four samples we had completely different results from
both assays (samples 3, 16, 18, and 28). The great divergence of
results between the EIA tests from two manufacturers (Ortho
and Abbott) with samples 3 and 16 (RIBA-negative, PCR-posi-
tive) is notable. Both samples showed high ratios of OD cutoff
(;;::::4.8) with the Ortho test; in contrast, ratios were ~0.17 with
the Abbott test.
In these cases, the 4 patients must be followed longer to estab-
lish the reason(s) for the divergent results: The RIBA-positive,
PCR-negative results may be due to low virus production, geno-
mic divergence of the isolate, or even false positivity of the
RIBA; the RIBA-negative, PCR-positive results may be due to
low antibody production by the patient or false positivity of the
PCR assay.
Safety and Immunogenicity of Salmonella typhi Ty21a
Liquid Formulation Vaccine in 4- to 6-Year-Old Thai
Children
Colleagues-Typhoid fever remains a serious public health
problem in many developing areas of the world [I, 2]. The at-
tenuated Salmonella typhi Ty21a vaccine strain confers signifi-
cant protection against typhoid fever without the-attendant ad-
verse reactions associated with the use of the parenteral vaccine
[3-5]. A liquid Ty21 a vaccine formulation has recently been
found to provide greater protection than the currently available
enteric-coated capsules in Chile and Indonesia [4, 5]. The vast
majority of the study populations were schoolchildren (>6 years
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In both cases in which the RIBA did not give clear results,
PCR turned out to be very valuable. Sample 7 had to be classi-
fied as indeterminate according to the manufacturer's instruc-
tions. Sample 10 came from the same patient but, unfortu-
nately, has not been tested by RIBA. However, PCR detected
viremia in both samples. For sample 12 the reactivity by PCR
gives support for the extreme weak positivity by RIBA.
Finally, the analysis of results suggests a division of patients
into four groups: Group I, patients with hepatitis due to HCV;
group 2, patients with hepatitis of unknown etiology; group 3,
probable false positivity of the ELISA; and group 4, patients to
be followed because of divergent RIBA and PCR results.
We believe that the use ofRIBA-2 and reverse transcriptase-
nested PCR in combination is an efficient way to improve the
quality of HCY diagnosis.
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of age) and young adults. It is becoming increasingly apparent
that there is a high incidence of S. typhi infection in children 2-5
years ofage. Unfortunately, comparatively little is known about
the safety and immunogenicity of the Ty21 a vaccine in this
high-risk age group [6].
Therefore, we conducted a randomized, double-blind, pla-
cebo-controlled trial to evaluate the safety and immunogenicity
of the liquid Ty21 a vaccine formulation in Thai children 4-6
years of age.
The study was conducted at 6 day care centers involving a
total of 170 healthy children. The vaccine and placebo were
packaged in identical-appearing aluminum foil sachets bearing a
letter code. Each dose of vaccine contained 3 X 109 cfu of S.
typhi Ty21 a, while each placebo packet contained 2 X 109 heat-
killed Escherichia coli K 12. Each buffer pack was composed of
1.3 g of sodium bicarbonate and 0.8 g of ascorbic acid. The
resuspended sachet was ingested within 10 min of preparation.
Upon reconstitution, the Ty21a bacteria remain viable for at
least 30 min. The children were observed by a physician for 1.5
h after vaccination for immediate reactions. Parents were given
an adverse reaction report sheet to complete after each vaccina-
tion. Three doses of vaccine or placebo were given on alternate
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days. A venous blood sample was collected immediately before
and 21 days after vaccination.
Anti-S. typhi lipopolysaccharide (LPS) antibody levels were
measured by ELISA [7, 8]. A significant rise in antibody level
(seroconversion) was defined as a net increase of0.15 00 units
above preimmunization values [7].
No adverse reactions that could be attributed to immuniza-
tion were reported by the 88 participants who received the
Ty21a vaccine. Of the 82 placebo recipients, 3 noted transient
symptoms such as malaise, headache, rash, and low-grade fever.
Paired serum samples were obtained from 160 children. The
serum anti-So typhi LPS antibody response is shown in table 1.
The seroconversion rate for vaccine recipients of all ages was
83%versus 14% for those who received the placebo (P < .005).
There was no difference in the response rate for children aged 4,
5, or 6 (80%-86%; P> .5). The seroconversion rate among pla-
cebo recipients was higher than would have been predicted. We
have not been able to pinpoint the reason for this observation.
Fully 37% of children (63/170) had elevated baseline anti-
body levels (00 ~ 0.75, based on levels in North American
volunteers who ingested S. typhi in vaccine challenge studies),
suggesting prior exposure to S. typhi or another group 0 Salmo-
nel/a species [7]. Of this subgroup, 89%of those who received
vaccine seroconverted (31/35), while only 39%ofplacebo recipi-
ents did so (11/28; P < .005). This finding indicates that vaccine
"take" is not inhibited by prior exposure to S. typhi and may
boost background levels of immunity.
Prior attempts to immunize young children with Ty21a
showed that --40% of children aged 6-9 years seroconverted,
while the response was meager (--20%) in 2- to 3.5-year-olds
[9]. The superior immunogenicity noted herein may be attrib-
uted to one or more factors including vaccine formulation,
Table 1. Anti-Salmonella typhi lipopolysaccharide antibody response fol-
lowing ingestion of S. tvphi Ty21a vaccine or placebo.
Age No. seroconverting/
(years) Formulation total (%) p*
4 Placebo 3/20 (15)
Vaccine 19/22(86) <.01
5 Placebo 6/36(16)
Vaccine 30/37 (80) <.01
6 Placebo 2/20 (10)
Vaccine 20/24 (83) <.01
Total Placebo 11/76(14)
Vaccine 69/83 (83) <.01
* Significance determined by x2 analysis.
higher level of previous exposure to S. typhi or group 0 Salmo-
nel/a species among Thai children, or genetic differences.
A significant risein serum IgG anti-So typhi LPSantibody was
found to correlate well with protection against disease in field
trials with school-age children in Santiago, Chile [3]. Therefore,
seroconversion may serve as an accurate marker of vaccine take
and predictor of immunity.
The excellent safety and immunogenicity record of the Ty21a
vaccine in 4- to 6-year-old Thai children paves the way for stud-
ies in younger children. At present, a study of similar design is
planned for 2- to 4-year-old children. If similar results are ob-
tained in this younger age group, it may prove possible to immu-
nize before the age at which disease incidence peaks, thereby
achieving the maximum public health benefit.
T. Olanratmanee, M. Levine, G. Losonsky, U. Thisyakorn,
and S. J. Cryz, Jr.
Chachoengsao Hospital, Chachoengsao, and Chulalongkorn University.
Bangkok, Thailand; Center for Vaccine Development, Baltimore.
Maryland; and Swiss Serum and Vaccine Institute, Berne, Switzerland
References
1. Thisyakorn U, Mansuwan P, Taylor ON. Typhoid and paratyphoid fever
in 192 children in Thailand. Am J Dis Child 1987;141:862-5.
2. Institute of Medicine. New vaccine development: establishing priorities.
Vol II. Diseases of importance in developing countries. Washington,
DC: National Academy Press, 1986. Appendix 0-14, Prospects for
immunizing against Salmonella typhi: 1-10.
3. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R, Chilean
Typhoid Committee. Progress in vaccines against typhoid fever. Rev
Infect Dis 1989;II(suppl 3):S552-67.
4. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated
capsules and liquid formulation ofTy21a typhoid vaccine in random-
ised controlled field trial. Lancet 1990;336:891-4.
5. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation
against typhoid fever in Indonesia with Ty21a vaccine. Lancet
1991;338: 1055-9.
6. Murphy JR, Grez L, Schlesinger L, et al. Immunogenicity of Salmonella
typhi Ty21a vaccine for young children. Infect Immun 1991;59:
4291-3.
7. Levine MM. Herrington 0, Murphy JR, et al. Safety, infectivity, irnrnu-
nogenicity, and in vivo stability oftwo attenuated auxotrophic mutant
strains of Salmonella typhi. J C1in Invest 1987;9:888-902.
8. Murphy JR, Baqar S, Munoz C, et al. Human immunity to Salmonella
typhi: some characteristics of humoral and cellular immunity of indi-
viduals resident in typhoid endemic and typhoid free regions. J Infect
Dis 1987; 156:1005-9.
9. Black RE, Levine MM. Young CR, et al. Immunogenicity of Ty21a
attenuated Salmonella typhi given with sodium bicarbonate or in en-
teric-coated capsules. BioI Stand 1983;53:9-14.
